June 21, 2021
Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion
ORION CORPORATION PRESS RELEASE 21 JUNE 2021 at 9.30 EEST Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
June 21, 2021
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
NEW YORK and LONDON, June 21, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology…
June 19, 2021
Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”…
June 19, 2021
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing…
June 19, 2021
Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock
Special meeting to be held virtually on July 13, 2021, at 9:00 a.m. Eastern TimeMALVERN, Pa., June 18, 2021 (GLOBE…
June 19, 2021
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission…
June 19, 2021
TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology
NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I…
June 19, 2021
New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline
All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for…
June 19, 2021
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., June 18, 2021 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused…
June 19, 2021
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors
– Second New Drug Application (“NDA”) approved for Sulanda in China – – The pivotal Phase III SANET-p trial demonstrated…